InsiderTrades

Form 4 for RLAY Relay Therapeutics, Inc.

Accepted 2026-06-24 16:09:22 ET · period of report 2026-06-22 · accession 0001193125-26-281059 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-06-24 16:09 2026-06-22 RLAY Bergstrom Donald A Pres, R, D M - OptEx $4.12 +93.5K 512.0K +22% +$385.0K
DT 2026-06-24 16:09 2026-06-22 RLAY Bergstrom Donald A Pres, R, D S - Sale+OE $16.94 -93.5K 418.6K -18% -$1.58M
DT 2026-06-24 16:09 2026-06-22 RLAY Bergstrom Donald A Pres, R, D M - OptEx $0.00 -93.5K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-22 M A 93,456 $4.12 512,013 D — — (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F2) Includes 15,037 shares underlying restricted stock units.
2 Common Common Stock 2026-06-22 S D 93,456 $16.94 418,557 D — — (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F2) Includes 15,037 shares underlying restricted stock units.
3 Derivative Stock Option (Right to Buy) 2026-06-22 M D 93,456 $0.00 0 D $4.12 · — to 2028-04-09 93,456 Common Stock (F1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. (F4) Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months.